NASDAQ:KIN - Kindred Biosciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$12.66 +0.36 (+2.93 %)
(As of 11/16/2018 02:30 AM ET)
Previous Close$12.30
Today's Range$12.22 - $12.83
52-Week Range$7.15 - $15.75
Volume80,900 shs
Average Volume165,661 shs
Market Capitalization$436.46 million
P/E Ratio-10.29
Dividend YieldN/A
Beta0.25
Kindred Biosciences, Inc., a biopharmaceutical company, focuses on the development of therapies for pets. The company's product pipeline includes small molecules and biologics for a range of indications in dogs, cats, and horses. Its lead product candidates comprise Zimeta, a dipyrone injection for the control of pyrexia (fever) in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. The company's other small molecule product candidates consist of KIND-014 for treatment of equine gastric ulcers in horses; and KIND-015 for the management of clinical signs related to equine metabolic syndrome. It is also developing biologics programs, including KIND-510, a feline recombinant erythropoietin for the control of non-regenerative anemia in cats; KIND-011, an anti-tumor necrosis factor (TNF) to treat newborn foals; and canine atopic dermatitis, an immune-mediated inflammatory, chronic skin disease related to allergies. In addition, the company engages in the development of other biologic product candidates, such as KIND-502 to treat allergic and immune-mediated diseases; KIND-0888, an antibody that targets CD20; various antibodies that target cytokines involved in atopic dermatitis; KIND-509, an antibody that targets the canine TNF; and KIND-Bodies, a biologics scaffold technology. Further, it is developing anti-IL31, anti-IL17, and anti-IL4/13 sink antibodies for treating atopic dermatitis in dogs; anti-TNF antibody for inflammatory bowel disease in dogs; anti-IgE antibody for treating allergic diseases in dogs; anti-VEGF antibody for cancer in dogs; anti-CD20 for treating cancer and autoimmune diseases in dogs; and checkpoint inhibitors to treat cancer in dogs. Kindred Biosciences, Inc. was founded in 2012 and is headquartered in Burlingame, California.

Receive KIN News and Ratings via Email

Sign-up to receive the latest news and ratings for KIN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KIN
Previous Symbol
CUSIPN/A
Phone650-701-7901

Debt

Debt-to-Equity RatioN/A
Current Ratio10.83
Quick Ratio10.55

Price-To-Earnings

Trailing P/E Ratio-10.29
Forward P/E Ratio-8.17
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.08 per share
Price / Book4.11

Profitability

EPS (Most Recent Fiscal Year)($1.23)
Net Income$-30,870,000.00
Net MarginsN/A
Return on Equity-46.17%
Return on Assets-43.28%

Miscellaneous

Employees63
Outstanding Shares33,910,000
Market Cap$436.46 million
OptionableOptionable

Kindred Biosciences (NASDAQ:KIN) Frequently Asked Questions

What is Kindred Biosciences' stock symbol?

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

How were Kindred Biosciences' earnings last quarter?

Kindred Biosciences Inc (NASDAQ:KIN) announced its quarterly earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.40) by $0.01. The biopharmaceutical company earned $0.64 million during the quarter. View Kindred Biosciences' Earnings History.

When is Kindred Biosciences' next earnings date?

Kindred Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, March 7th 2019. View Earnings Estimates for Kindred Biosciences.

What price target have analysts set for KIN?

9 brokerages have issued 12 month price objectives for Kindred Biosciences' stock. Their predictions range from $16.75 to $25.00. On average, they anticipate Kindred Biosciences' share price to reach $20.4375 in the next twelve months. This suggests a possible upside of 61.4% from the stock's current price. View Analyst Price Targets for Kindred Biosciences.

What is the consensus analysts' recommendation for Kindred Biosciences?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kindred Biosciences.

What are Wall Street analysts saying about Kindred Biosciences stock?

Here are some recent quotes from research analysts about Kindred Biosciences stock:
  • 1. According to Zacks Investment Research, "Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes. " (11/13/2018)
  • 2. Cantor Fitzgerald analysts commented, ". Post positive top-line results from the company’s pilot effectiveness study of KIND-016, we reiterate our Overweight rating and raise our 12-month price target to $25 from $20. Our price-target increase is driven by an increased conviction about KIN’s antibody pipeline, which includes KIND-016, a fully caninized, high-affinity IL-31 monoclonal antibody for the treatment of atopic dermatitis in dogs, an IL4/IL13 product that is likely to readout in early 2019, and by a number of undisclosed antibody products that the company is working on but has not yet disclosed." (10/31/2018)

Has Kindred Biosciences been receiving favorable news coverage?

News headlines about KIN stock have trended somewhat positive recently, InfoTrie reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kindred Biosciences earned a media sentiment score of 1.2 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.

Who are some of Kindred Biosciences' key competitors?

Who are Kindred Biosciences' key executives?

Kindred Biosciences' management team includes the folowing people:
  • Dr. Richard Chin, Co-Founder, Pres, CEO & Director (Age 51)
  • Ms. Denise M. Bevers, Co-Founder, COO & Sec. (Age 51)
  • Ms. Wendy K. Wee, Chief Financial Officer (Age 65)
  • Dr. Hangjun Zhan, Chief Scientific Officer (Age 58)
  • Ms. Katja Buhrer, VP of Corp. Devel. & Investor Relations

Who are Kindred Biosciences' major shareholders?

Kindred Biosciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.41%), Renaissance Technologies LLC (3.11%), General American Investors Co. Inc. (1.36%), Allianz Asset Management GmbH (0.74%), Wells Fargo & Company MN (0.50%) and EAM Investors LLC (0.42%). Company insiders that own Kindred Biosciences stock include Park West Asset Management Llc, Raymond Townsend and Richard Chin. View Institutional Ownership Trends for Kindred Biosciences.

Which institutional investors are selling Kindred Biosciences stock?

KIN stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, General American Investors Co. Inc., NJ State Employees Deferred Compensation Plan, JPMorgan Chase & Co., JPMorgan Chase & Co. and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have sold Kindred Biosciences company stock in the last year include Raymond Townsend and Richard Chin. View Insider Buying and Selling for Kindred Biosciences.

Which institutional investors are buying Kindred Biosciences stock?

KIN stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Allianz Asset Management GmbH, Renaissance Technologies LLC, EAM Global Investors LLC, EAM Investors LLC, Man Group plc, Strs Ohio and Bank of New York Mellon Corp. View Insider Buying and Selling for Kindred Biosciences.

How do I buy shares of Kindred Biosciences?

Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kindred Biosciences' stock price today?

One share of KIN stock can currently be purchased for approximately $12.66.

How big of a company is Kindred Biosciences?

Kindred Biosciences has a market capitalization of $436.46 million. The biopharmaceutical company earns $-30,870,000.00 in net income (profit) each year or ($1.23) on an earnings per share basis. Kindred Biosciences employs 63 workers across the globe.

What is Kindred Biosciences' official website?

The official website for Kindred Biosciences is http://www.kindredbio.com.

How can I contact Kindred Biosciences?

Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]


MarketBeat Community Rating for Kindred Biosciences (NASDAQ KIN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  236 (Vote Outperform)
Underperform Votes:  227 (Vote Underperform)
Total Votes:  463
MarketBeat's community ratings are surveys of what our community members think about Kindred Biosciences and other stocks. Vote "Outperform" if you believe KIN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KIN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/16/2018 by MarketBeat.com Staff

Featured Article: What is intrinsic value?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel